{"protocolSection": {"identificationModule": {"nctId": "NCT00243165", "orgStudyIdInfo": {"id": "LifemelCTIL"}, "organization": {"fullName": "Rambam Health Care Campus", "class": "OTHER"}, "briefTitle": "Lifemel Honey to Reduce Leucopenia During Chemotherapy", "officialTitle": "Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia"}, "statusModule": {"statusVerifiedDate": "2005-10", "overallStatus": "UNKNOWN", "lastKnownStatus": "NOT_YET_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-11"}, "studyFirstSubmitDate": "2005-10-20", "studyFirstSubmitQcDate": "2005-10-20", "studyFirstPostDateStruct": {"date": "2005-10-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2009-12-04", "lastUpdatePostDateStruct": {"date": "2009-12-07", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"leadSponsor": {"name": "Rambam Health Care Campus", "class": "OTHER"}, "collaborators": [{"name": "Zuf Globus Laboratories Ltd.", "class": "OTHER"}]}, "descriptionModule": {"briefSummary": "This study will include 60 patients with early breast cancer referred to receive adjuvant chemotherapy with AC ( adriamycin- cyclophosphamide) or CAF ( adriamycin- cyclophosphamide- 5- fluorouracil ) combinations. These patients will receive every day one spoon of Lifemel honey or regular honey ( double blind)- during the adjuvant chemotherapy .Every week a WBC count will be performed in order to record the influence of Lifemel on myelotoxicity."}, "conditionsModule": {"conditions": ["Breast Cancer"], "keywords": ["breast cancer", "honey", "myelosuppression", "chemotherapy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 60, "type": "ESTIMATED"}}, "armsInterventionsModule": {"interventions": [{"type": "BEHAVIORAL", "name": "Lifemel honey intake every day"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Prevention of myelotoxicity-every week during chemotherapy."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* breast cancer patient treated with adjuvant chemotherapy\n* PS = 2 or less\n\nExclusion Criteria:\n\n* none", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Georgeta Fried, MD", "role": "CONTACT", "phone": "972-4-8543018", "email": "g_fried@rambam.health.gov.il"}], "overallOfficials": [{"name": "Georgeta Fried, MD", "affiliation": "Rambam Health Care Campus", "role": "PRINCIPAL_INVESTIGATOR"}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-19"}, "conditionBrowseModule": {"meshes": [{"id": "D001943", "term": "Breast Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}}, "hasResults": false}
{"protocolSection": {"identificationModule": {"nctId": "NCT05131607", "orgStudyIdInfo": {"id": "STUDY02001039"}, "organization": {"fullName": "Dartmouth-Hitchcock Medical Center", "class": "OTHER"}, "briefTitle": "21DIF039: Prone to Supine Breast MRI II, P2S2 Breast MRI Trial", "officialTitle": "Prone to Supine Breast MRI Trial II, P2S2 MRI Trial", "acronym": "21DIF039"}, "statusModule": {"statusVerifiedDate": "2024-01", "overallStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2022-03-17", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-07-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2024-03-31", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2021-10-15", "studyFirstSubmitQcDate": "2021-11-12", "studyFirstPostDateStruct": {"date": "2021-11-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-01-29", "lastUpdatePostDateStruct": {"date": "2024-01-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Roberta diFlorio-Alexander", "investigatorTitle": "Staff Physician, Radiology", "investigatorAffiliation": "Dartmouth-Hitchcock Medical Center"}, "leadSponsor": {"name": "Dartmouth-Hitchcock Medical Center", "class": "OTHER"}, "collaborators": [{"name": "CairnSurgical, Inc.", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether a supine breast MRI obtained with a second intravenous injection of gadolinium contrast immediately after a standard clinical prone breast MRI will provide sufficient tumor visualization to allow a Radiologist to define and outline the tumor edges (\"segment\" the tumor). Accurate segmentation will allow a 3-D image of the tumor to be generated to create a breast cancer locator (BCL) surgical device to in aid removal of breast cancers.", "detailedDescription": "The clinical pre-operative breast MRI exam will be obtained in the prone position with intravenous (IV) Gadolinium (Gd) contrast injection per standard of care clinical protocol. After completion of the standard clinical prone breast MRI, the participant will be re-positioned and the investigative supine breast MRI protocol with a second dose of IV Gd will be obtained. A second dose of contrast equal to the first dose will be given, and additional images will be obtained in the supine position. Subtraction images will be generated for both the prone and the supine sequences. It is hypothesized that the second contrast injection will generate tumor-to-fibroglandular contrast differences such that supine subtraction images will allow visualization and segmentation of the tumor equal to prone segmentation images. It is expected that the addition of a second injection of contrast will improve the ability to visualize and accurately segment the supine post-Gd images. While the total dose of gadolinium delivered in two injections is twice the amount normally given during a clinical prone breast MRI, this total dose is equal to that administered for other clinical MRI studies such as cardiac MRI.\n\nNo additional imaging or testing will be required for this research study following the standard clinical MRI."}, "conditionsModule": {"conditions": ["Breast Cancer Female"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 45, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Supine MRI", "type": "EXPERIMENTAL", "interventionNames": ["Procedure: Supine MRI"]}], "interventions": [{"type": "PROCEDURE", "name": "Supine MRI", "description": "After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained", "armGroupLabels": ["Supine MRI"], "otherNames": ["Prone to Supine Breast MRI II, P2S2 MRI Trial"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Difference in mean tumor-to-fibroglandular contrast ratio in prone compared to supine breast MRI", "description": "Determine the mean tumor-to-fibroglandular contrast in a two bolus intravenous contrast injection prone to supine breast MRI study and compare this to the mean tumor-to-fibroglandular contrast of a single-contrast injection prone to supine breast MRI study.", "timeFrame": "Day of standard clinical MRI, 1 day"}], "secondaryOutcomes": [{"measure": "Evaluate tumor visualization and segmentability on supine breast MRI exam with additional contrast injection obtained immediately after prone contrast breast MRI, and compare to tumor visualization and segmentability on clinical prone breast MRI.", "description": "Compare the proportion of cases with successful agreement between radiologists' segmentation volumes in the double-contrast dose prone to supine MRI study to proportion of cases with successful agreement in the single-contrast dose prone to supine MRI using a Hausdorff Distance (HD) threshold \\< 1 cm.", "timeFrame": "Day of MRI, 1 day"}], "otherOutcomes": [{"measure": "Evaluate time required for double contrast prone to supine exam compared to single contrast prone to supine exam.", "description": "Determine the time required to obtain the double contrast prone to supine exam by recording start and stop times of both Supine and Prone MRI, using minutes and seconds. Compare exam time to single contrast prone to supine (prior study)", "timeFrame": "Day of MRI, 1 day"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. Female gender.\n3. Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ.\n4. Tumor size at least 1 cm in diameter as visualized on mammogram or US.\n5. A staging, pre-operative breast MRI is considered to be clinically indicated.\n6. Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.\n\nExclusion Criteria:\n\n1. Absolute contraindication to MRI, including presence of implanted electrical device. (pacemaker or neurostimulator incompatible with MRI), aneurysm clip, or metallic foreign body in or near eyes.\n2. Severe claustrophobia.\n3. Contraindication to the use of gadolinium-based intravenous contrast, including anaphylaxis. Any known history of nephrogenic systemic fibrosis (NSF).\n4. History of median sternotomy.\n5. Pregnancy. All women of child-bearing age will be questioned about possible pregnancy status. In women who are unsure of pregnancy status, a urine pregnancy test will be performed.\n6. Patients who have received neoadjuvant chemotherapy for their current diagnosis.\n7. Known compromised renal function including chronic, severe kidney disease (GFR \\< 30 ml/min/1.73m2), or acute kidney injury.", "healthyVolunteers": false, "sex": "FEMALE", "genderBased": true, "genderDescription": "Female", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Roberta diFlorio-Alexander, MD", "affiliation": "DHMC", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Dartmouth-Hitchcock Medical Center", "city": "Lebanon", "state": "New Hampshire", "zip": "05055", "country": "United States", "geoPoint": {"lat": 43.64229, "lon": -72.25176}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "annotationSection": {"annotationModule": {"unpostedAnnotation": {"unpostedResponsibleParty": "Roberta diFlorio-Alexander, Staff Physician, Radiology, Dartmouth-Hitchcock Medical Center", "unpostedEvents": [{"type": "RELEASE", "date": "2024-10-17"}, {"type": "RESET", "date": "2024-12-02"}]}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-19", "submissionTracking": {"estimatedResultsFirstSubmitDate": "2024-10-17", "submissionInfos": [{"releaseDate": "2024-10-17", "resetDate": "2024-12-02"}]}}}, "hasResults": false}
{"protocolSection": {"identificationModule": {"nctId": "NCT01219907", "orgStudyIdInfo": {"id": "7266"}, "secondaryIdInfos": [{"id": "NCI-2010-01792"}], "organization": {"fullName": "University of Washington", "class": "OTHER"}, "briefTitle": "Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer", "officialTitle": "Phase I Study of Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes Obtained Following In Vivo Priming With a Peptide Vaccine in Patients With Advanced Stage HER-2-Positive Breast Cancer"}, "statusModule": {"statusVerifiedDate": "2013-05", "overallStatus": "WITHDRAWN", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-06"}, "primaryCompletionDateStruct": {"date": "2014-06", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2010-09-22", "studyFirstSubmitQcDate": "2010-10-11", "studyFirstPostDateStruct": {"date": "2010-10-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-05-15", "lastUpdatePostDateStruct": {"date": "2013-05-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Salazar, Lupe", "oldOrganization": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"}, "leadSponsor": {"name": "University of Washington", "class": "OTHER"}, "collaborators": [{"name": "National Cancer Institute (NCI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "RATIONALE : Laboratory-treated T cells may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from HER2 peptides may help the body build an effective immune response to kill tumor cells that express HER2. Giving laboratory-treated T cells and cyclophosphamide after vaccine therapy may be an effective treatment for breast cancer.\n\nPURPOSE: This phase I trial is studying the side effects and best dose of ex vivo-expanded HER2-specific T cells when given together with cyclophosphamide after vaccine therapy in treating patients with HER2-positive stage IV breast cancer.", "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To evaluate the feasibility of expanding HER-2-specific effector T cells (TE) ex vivo from CD62L+ TCM and CD62L- TEM from patients immunized with a HER-2 peptide vaccine.\n\nII. To evaluate the safety of infusing autologous ex vivo expanded HER-2-specific T cells into patients with advanced HER-2+ breast cancer.\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate the persistence, function, and phenotype of adoptively transferred HER-2-specific TE cells derived from TCM or TEM precursors.\n\nII. To investigate the potential anti-tumor effects of therapy with ex vivo expanded HER-2-specific T cells in patients with advanced HER-2+ breast cancer.\n\nOUTLINE : This is a dose-escalation study of ex vivo-expanded HER2-specific T cells.\n\nVACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.\n\nCHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.\n\nIMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20.\n\nAfter completion of study treatment, patients are followed up on days 28, 35, 49, 63 and then monthly thereafter for 1 year."}, "conditionsModule": {"conditions": ["HER2-positive Breast Cancer", "Male Breast Cancer", "Stage IV Breast Cancer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 0, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm I", "type": "EXPERIMENTAL", "description": "VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.\n\nCHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.\n\nIMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20.", "interventionNames": ["Biological: HER-2/neu peptide vaccine", "Drug: cyclophosphamide", "Biological: ex vivo-expanded HER2-specific T cells", "Other: laboratory biomarker analysis", "Other: flow cytometry", "Other: immunoenzyme technique"]}], "interventions": [{"type": "BIOLOGICAL", "name": "HER-2/neu peptide vaccine", "description": "Given intradermally", "armGroupLabels": ["Arm I"], "otherNames": ["HER-2"]}, {"type": "DRUG", "name": "cyclophosphamide", "description": "Given IV", "armGroupLabels": ["Arm I"], "otherNames": ["CPM", "CTX", "Cytoxan", "Endoxan", "Endoxana", "Enduxan"]}, {"type": "BIOLOGICAL", "name": "ex vivo-expanded HER2-specific T cells", "description": "Given IV", "armGroupLabels": ["Arm I"]}, {"type": "OTHER", "name": "laboratory biomarker analysis", "description": "Correlative studies", "armGroupLabels": ["Arm I"]}, {"type": "OTHER", "name": "flow cytometry", "description": "Correlative studies", "armGroupLabels": ["Arm I"]}, {"type": "OTHER", "name": "immunoenzyme technique", "description": "Correlative studies", "armGroupLabels": ["Arm I"], "otherNames": ["immunoenzyme techniques"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Ability to expand HER-2-specific T cells ex vivo from memory T cell subsets which are derived from patients with advanced HER-2 expressing cancer", "description": "Ability to expand HER-2-specific T cells ex vivo from memory T cell subsets which are derived from patients with advanced HER-2 expressing cancer will be defined as feasible if the minimum target expansion of HER-2-specific T cells is achieved in ≥2/3 expansions in ≥7/10 subjects.", "timeFrame": "After leukapheresis (2 weeks after 3rd vaccination) and prior to chemotherapy"}, {"measure": "Safety and systemic toxicity as assessed at regular time points by NCI common toxicity criteria (CTCAE v 4.0). Stopping rules for the study protect patients against therapy with a rate of severe toxicity of 20% or greater.", "timeFrame": "At week 1, 2, 3, post T-Cell infusion day 1, 10, 20, 28, 35, 49, 63, then every 3 months for a year."}], "secondaryOutcomes": [{"measure": "Extent to which to HER-2-specific T cell immunity can be boosted successfully with adoptive immunotherapy will be defined by quantitative assessment of HER-2-specific CD8+ T cells assessed by cytokine flow cytometry (CFC), Elispot, and tetramer staining", "timeFrame": "Post T-Cell-infusion on day 10, 20, 28, 35, 49, 63, then monthly for one year."}, {"measure": "Persistence of T cell immune augmentation in vivo after adoptive transfer of HER-2-specific T cells as assessed by presence of HER-2-specific central memory T cells and effector memory T cells", "timeFrame": "Every month for 1 year following the last infusion"}, {"measure": "Anti-tumor effects of HER-2-specific T cells as assessed by RECIST criteria", "timeFrame": "Day 63 post transplant"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with HER-2+ Stage IV breast cancer that have been maximally treated and not in a complete remission\n* Subjects must be \\> 18 years old\n* Extra skeletal disease that can be accurately measured in at least one dimension as \\>= 20 mm with conventional CT techniques or \\>= 10 mm with spiral CT scan\n* Skeletal or bone-only disease that is measurable by FDG PET imaging will also be allowed\n* Patients can be receiving trastuzumab and/or hormonal therapy and/or bisphosphonates\n* HER2 overexpression in the primary tumor or metastasis by IHC of 2+ or 3+, or documented gene amplification by FISH analysis; if over expression is 2+ by IHC, patients must have HER2 gene amplification documented by FISH\n* Performance Status Score (ECOG/Zubrod Scale) must be =\\< 2\n* Patients must be off all immunosuppressive treatments such as chemotherapy or systemic steroid therapy a minimum of 3 weeks prior to initiation of study (i.e. first vaccination)\n* Patients on trastuzumab must have a baseline LVEF measured by MUGA or echocardiogram \\>= the lower limit of normal for the facility within 3 months of enrollment to study\n* Subjects must be HLA-A2 (HLA A\\*0201) positive\n* ANC \\>= 1000/mm\\^3\n* Hgb \\>= 10 mg/dl\n* Platelet count \\>= 75,000/mm\\^3\n* Men and women of reproductive ability must agree to use contraceptives during the entire study period\n\nExclusion Criteria:\n\n* Serum creatinine \\> 2.0 mg/dl\n* Serum bilirubin \\> 2.5 times the upper limit of normal\n* Contraindication to receiving GM-CSF based vaccine products\n* New York Heart Association functional class III-IV heart failure, symptomatic pericardial effusion, or unstable angina\n* History of disorders associated with immunosuppression such as HIV\n* Pregnant or breast-feeding women\n* ANC \\< 1000/mm\\^3\n* Hgb \\< 10 mg/dl\n* Platelet count \\< 75,000/mm\\^3\n* Active brain metastasis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lupe Salazar", "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "city": "Seattle", "state": "Washington", "zip": "98109", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2025-09-19"}, "conditionBrowseModule": {"meshes": [{"id": "D018567", "term": "Breast Neoplasms, Male"}, {"id": "D001943", "term": "Breast Neoplasms"}], "ancestors": [{"id": "D009371", "term": "Neoplasms by Site"}, {"id": "D009369", "term": "Neoplasms"}, {"id": "D001941", "term": "Breast Diseases"}, {"id": "D012871", "term": "Skin Diseases"}, {"id": "D017437", "term": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D003520", "term": "Cyclophosphamide"}, {"id": "D005434", "term": "Flow Cytometry"}, {"id": "D007124", "term": "Immunoenzyme Techniques"}], "ancestors": [{"id": "D010752", "term": "Phosphoramide Mustards"}, {"id": "D009588", "term": "Nitrogen Mustard Compounds"}, {"id": "D009150", "term": "Mustard Compounds"}, {"id": "D006846", "term": "Hydrocarbons, Halogenated"}, {"id": "D006838", "term": "Hydrocarbons"}, {"id": "D009930", "term": "Organic Chemicals"}, {"id": "D063088", "term": "Phosphoramides"}, {"id": "D009943", "term": "Organophosphorus Compounds"}, {"id": "D002469", "term": "Cell Separation"}, {"id": "D003584", "term": "Cytological Techniques"}, {"id": "D019411", "term": "Clinical Laboratory Techniques"}, {"id": "D019937", "term": "Diagnostic Techniques and Procedures"}, {"id": "D003933", "term": "Diagnosis"}, {"id": "D003592", "term": "Cytophotometry"}, {"id": "D005470", "term": "Fluorometry"}, {"id": "D008163", "term": "Luminescent Measurements"}, {"id": "D010783", "term": "Photometry"}, {"id": "D002623", "term": "Chemistry Techniques, Analytical"}, {"id": "D008919", "term": "Investigative Techniques"}, {"id": "D007118", "term": "Immunoassay"}, {"id": "D007158", "term": "Immunologic Techniques"}, {"id": "D007150", "term": "Immunohistochemistry"}, {"id": "D015336", "term": "Molecular Probe Techniques"}]}}, "hasResults": false}
